Z. Jing (Beijing, China), J. Weatherald (Calgary (AB), Canada), H. Olschewski (Graz, Austria), G. Simonneau (Le Kremlin-Bicêtre, France)
Pharmacokinetic (PK) interaction of fixed-dose combination (FDC) antiretrovirals (ARV) with riociguat (rio) E. Dejesus (Florida, United States of America), S. Saleh (Wuppertal, Germany), D. Van Der Mey (Wuppertal, Germany), C. Becker (Wuppertal, Germany), R. Frey (Wuppertal, Germany), S. Unger (Wuppertal, Germany), W. Mueck (Wuppertal, Germany)
| |
Clinical pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet J. Grundy (San Diego, United States of America), A. Blackburn (San Diego, United States of America), E. Parsley (San Diego, United States of America), Y. Tang (San Diego, United States of America), C. King (San Diego, United States of America), J. Adams (San Diego, United States of America)
| |
Inhaled liposomal iloprost shows high drug encapsulation, extended release profile and potentials of improving patient compliance P. Kan (Taipei, Taiwan), . Chen (Taipei, Taiwan), C. Hsu (Taipei, Taiwan), Y. Lin (Taipei, Taiwan)
| |
Acute response of iloprost inhalation using the Breelib nebulizer in pulmonary arterial hypertension: the Breelib acute study M. Richter (Giessen, Germany), J. Axmann (Giessen, Germany), A. Ghofrani (Giessen, Germany), A. Rieth (Bad Nauheim, Germany), W. Seeger (Giessen, Germany), K. Tello (Giessen, Germany), H. Gall (Giessen, Germany)
| |
Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension R. Adão (Porto, Portugal), P. Mendes-Ferreira (Porto, Portugal), D. Santos-Ribeiro (Porto, Portugal), C. Maia-Rocha (Porto, Portugal), L. Pimentel (Porto, Portugal), C. Pinto (Porto, Portugal), E. Mulvaney (Dublin, Ireland), H. Reid (Dublin, Ireland), B. Kinsella (Dublin, Ireland), F. Potus (Quebec, Canada), S. Breuils-Bonnet (Quebec, Canada), M. Rademaker (Christchurch, New Zealand), S. Provencher (Quebec, Canada), S. Bonnet (Quebec, Canada), A. Leite-Moreira (Porto, Portugal), C. Brás-Silva (Porto, Portugal)
| |
Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study) A. Marra (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), C. Fischer (Heidelberg, Germany), H. Gall (Giessen, Germany), H. Ghofrani (Giessen, Germany), M. Halank (Dresden, Germany), M. Hoeper (Hannover, Germany), T. Lange (Regensburg, Germany), K. Olsson (Hannover, Germany), E. Grünig (Heidelberg, Germany)
| |
Interim analysis of pulmonary arterial hypertension (PAH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry) V. McLaughlin (Ann Arbor, United States of America), K. Chin (Dallas, United States of America), H. Farber (Boston, United States of America), K. Highland (Cleveland, United States of America), A. Hemnes (Nashville, United States of America), M. Chakinala (St. Louis, United States of America), C. Zhao (South San Francisco, United States of America), M. Keating (South San Francisco, United States of America), N. Kim (San Diego, United States of America)
| |
Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP) A. Jaureguizar Oriol (Madrid, Spain), E. Barbero Herranz (Madrid, Spain), C. Quezada Loaiza (Madrid, Spain), D. Barrios Barreto (Madrid, Spain), A. Román Broto (Barcelona, Spain), J. Segovia Cubero (Madrid, Spain), T. Elías Hernández (Sevilla, Spain), S. Cadenas Menéndez (Salamanca, Spain), P. Bedate Díaz (Asturias, Spain), I. Blanco Vich (Barcelona, Spain), P. Escribano Subías (Madrid, Spain)
| |
Switching to macitentan in pulmonary arterial hypertension I. Tsagkaris (Athens, Greece), E. Vrigkou (Athens, Greece), D. Konstantonis (Athens, Greece), F. Frantzeskaki (Athens, Greece), A. Pappas (Athens, Greece), K. Ntaï (Athens, Greece), E. Stagaki (Athens, Greece), A. Armaganidis (Athens, Greece), S. Orfanos (Athens, Greece)
| |
A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome H. Nashat (London, United Kingdom), C. Harries (London, United Kingdom), L. Parfitt (London, United Kingdom), E. Shaw (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom)
| |
Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension J. Sandoval Zarate (Mexico City, Mexico), R. Teijeiro Paradis (Mexico City, Mexico), T. Pulido Zamudio (Mexico City, Mexico), N. Zayas Hernadnez (Mexico City, Mexico), L. Del Valle (Mexico City, Mexico), F. Massó (Mexico City, Mexico), H. Gonzalez (Mexico City, Mexico), C. Sisniega (Mexico City, Mexico), G. Pastelin (Mexico City, Mexico)
| |
Cough and airway irritation with inhaled treprostinil does not involve activation of laryngeal reflexes. R. Chapman (Bridgewater, United States of America), W. Perkins (Bridgewater, United States of America), V. Malinin (Bridgewater, United States of America), D. Konicek (Bridgewater, United States of America), A. Plaunt (Bridgewater, United States of America), Z. Li (Bridgewater, United States of America), H. Gauani (Bridgewater, United States of America), A. Bouchard (Sherbrooke, QC, Canada), S. Gagnon (Sherbrooke, QC, Canada), L. Turcotte (Sherbrooke, QC, Canada), C. Laurent (Sherbrooke, QC, Canada), D. Salvail (Sherbrooke, QC, Canada), M. Corboz (Bridgewater, United States of America)
| |
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension A. Kambakamba (Giessen, Germany), K. Tello (Giessen, Germany), J. Axmann (Giessen, Germany), H. Gall (Giessen, Germany), A. Ghofrani (Giessen, Germany), S. Guth (Bad Nauheim, Germany), C. Wiedenroth (Bad Nauheim, Germany), M. Richter (Giessen, Germany)
| |
Efficacy and safety of tadalafil in portopulmonary hypertension M. Jevnikar (Le Kremlin-Bicêtre, France), N. Ebstein (Le Kremlin-Bicêtre, France), X. Jais (Le Kremlin-Bicêtre, France), A. Boucly (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), O. Sitbon (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France)
| |
The effects of a 10-weeks-pulmonary rehabilitation program on exercise performance, muscle strength and quality of life in patients with pulmonary hypertension. T. Koudstaal (Rotterdam, Netherlands), M. Wapenaar (Rotterdam, Netherlands), D. Van Ranst (Breda, Netherlands), R. Beesems (Breda, Netherlands), L. Van Den Toorn (Rotterdam, Netherlands), K. Boomars (Rotterdam, Netherlands)
| |
Clinical efficacy of Macitentan in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension H. Nashat (London, United Kingdom), R. Da Costa (London, United Kingdom), J. Barbosa (London, United Kingdom), C. Harries (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), C. Mc Cabe (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom)
| |
Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) M. Gabrielly (Le Kremlin Bicêtre, France), D. Bourlier (Pessac, France), Y. Taniguchi (Le Kremlin Bicêtre, France), M. Jevnikar (Le Kremlin Bicêtre, France), A. Sekine (Le Kremlin Bicêtre, France), A. Boucly (Le Kremlin Bicêtre, France), E. Jutant (Le Kremlin Bicêtre, France), F. Parent (Le Kremlin Bicêtre, France), L. Savale (Le Kremlin Bicêtre, France), D. Montani (Le Kremlin Bicêtre, France), G. Simonneau (Le Kremlin Bicêtre, France), M. Humbert (Le Kremlin Bicêtre, France), O. Sitbon (Le Kremlin Bicêtre, France), X. Jais (Le Kremlin Bicêtre, France)
| |
Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan N. Tanabe (Chiba, Japan), T. Ogo (Osaka, Japan), M. Hatano (Tokyo, Japan), Y. Tazaki (Osaka, Japan), T. Sunaya (Osaka, Japan), A. Saikawa (Osaka, Japan), T. Sakaguchi (Osaka, Japan)
| |
Effects of sildenafil as a bridge therapy for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension S. Fukui (Osaka, Japan), M. Palazzini (Bologna, Italy), E. Gotti (Bologna, Italy), D. Pacini (Bologna, Italy), S. Suarez (Bologna, Italy), T. Ogo (Osaka, Japan), S. Yasuda (Osaka, Japan), A. Manes (Bologna, Italy), N. Nakanishi (Osaka, Japan), N. Galié (Bologna, Italy)
| |